Page 73 of 160: studies 721 to 730 of 1,593, newest first. Back to the DMT overview
BMJ March 20, 2026 Jeffrey K Aronson 1 citation
Psychedelic drugs produce effects on the mind that manifest as an apparent expansion of consciousness often accompanied by hallucinations. Psychedelics, which act as agonists at serotonin 5-HT2A receptors in the brain, include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (tryptamine derivatives), mescaline (a phenethylamine derivative), and lysergic acid diethylamide...
Canadian Journal of Public Health March 19, 2026 Jenna Matsukubo, Erik Loewen Friesen, Rachael MacDonald-Spracklin et al. 1 citation
IntroductionThe use of psychedelics has increased in Canada in recent years. Although non-medical psilocybin use is prohibited under the Controlled Drugs and Substances Act, we previously documented the emergence of grey-market brick-and-mortar psilocybin retailers. This study examined changes in the number, composition, and geographic distribution of Canadian psilocybin retail stores between...
Scientific Reports March 18, 2026 Jonas T. T. Schlomberg, Daniel Meling, Robin Grylka et al.
The acute subjective effects (ASEs) of psychedelic substances are assumed to play a critical role for their therapeutic and well-being enhancing benefits. However, recent work voiced critique regarding the validity and adequacy of conventional measures and modalities utilized to study ASEs of psychedelics, and call for data-driven, unbiased, and experience-based research approaches. The...
Brain medicine March 17, 2026 Gabriella Gobbi
This Genomic Press Interview features Dr. Gabriella Gobbi, Professor of Psychiatry at McGill University, Canada Research Chair (Tier 1) in Therapeutics for Mental Health, Staff Psychiatrist at the McGill University Health Center (MUHC), and Senior Scientist, Brain Repair and Integrative Neuroscience Program at the Research Institute of the MUHC. Trained in medicine and psychiatry at the...
CNS & Neurological Disorders - Drug Targets March 11, 2026 Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain et al.
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...
ChemRxiv March 2, 2026 William Charles Hosie, Artem Pyrozhok, Massimo Filgiomeni et al. preprint
Clinical trials of psychedelics have shown preliminary promise for the treatment of psychiatric conditions such as major depressive disorder, substance use disorder, and treatment resistant depression.The most common psychedelic administration routes explored so far include intravenous injection, heated vapor inhalation, or a simple buffered salt solution administered to the nasal cavity.Given...
March 2, 2026 Rebekah Senānāyaka preprint
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequately capture its multidimensional nature.Objective: To develop and validate the Multidimensional Ego-Dissolution Assessment (MEDA) and examine substance-specific patterns across classical psychedelics.Methods: Items from three validated scales...
Drug and Alcohol Dependence Reports March 1, 2026 Jing-Jer Chen, Carla J. Berg, Y Tony Yang 1 citation
While interest in the therapeutic and recreational use of hallucinogens has increased, national surveillance often reports use in aggregate, potentially masking shifting trends among pharmacologically distinct substances. This study assessed trends in specific hallucinogens from 2021 to 2023 and identified correlates of use, with particular attention to subgroup patterns in populations commonly...
February 24, 2026 Momoko Ishii, Mark Zervas
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methylenedioxymethamphetamine) act on serotonergic-related neural circuits and function as serotonin modulators. All three molecules are either currently used or proposed as novel therapeutic modalities to treat P ost- T raumatic S tress D isorder (PTSD)....
Frontiers in Molecular Biosciences February 18, 2026 Gabriella de Souza Gomes Ribeiro, Beatriz Aparecida Passos Bismara Paranhos, Fabiane Dörr et al. 1 citation
The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotonergic effects in individuals receiving antidepressant therapy. This study provides a mechanistic and quantitative framework for assessing interaction risks between ayahuasca alkaloids and SSRIs, supporting clinical decision-making and harm-reduction...